{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-032286","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2022-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.521407+00:00","generated_at":"2026-06-23T07:35:57.953526+00:00","sec_items":["8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"EVP Endocrine Business Unit Alejandro Galindo resigns effective Oct 21, 2022","bullets":["Alejandro Galindo, Executive Vice President – Endocrine Business Unit, resigns to pursue other opportunity.","Resignation effective at close of business on October 21, 2022.","No replacement named or additional details provided in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-032286","json":"https://secwatch.observer/filing/0001564590-22-032286.json","markdown":"https://secwatch.observer/filing/0001564590-22-032286.md","text":"https://secwatch.observer/filing/0001564590-22-032286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000156459022032286/0001564590-22-032286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000156459022032286/mnkd-8k_20220923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:35:57.953526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}